RNAi Returns To Spotlight As Novo Nordisk Swoops For Dicerna
The Denmark-headquartered major is impressed with what it has seen in Dicerna in the two years since the companies teamed up and is paying an 80% premium to get hold of the US firm's RNAi technology platforms.
You may also be interested in...
Tsai and Schaffert out as the Swiss giant looks to maximize returns from its US business, and find more transformational drugs with the help of a new ‘strategy and growth officer’.
There is more to the Danish major than diabetes and Ludovic Helfgott gave In Vivo an insight to the firm’s ambitious plans for its renamed rare diseases division.
The potential for RNA medicines to achieve holy grail goals – reaching undruggable targets and bringing drugs to market faster – has Pfizer, Lilly, Novartis and others in a deal-making frame of mind.